Prevention of docetaxel?associated febrile neutropenia with primary granulocyte colony?stimulating factor in Chinese metastatic hormone?sensitive and castration?resistant prostate cancer patients

Introduction Asian prostate cancer (PC) patients are particularly susceptible to docetaxel-related febrile neutropenia (FN). We evaluated primary granulocyte colony-stimulating factor (GCSF) for preventing FN in Chinese with metastatic hormone-sensitive PC (mHSPC) and castration-resistant (mCRPC). Patients methods Data from two cohorts of 377 mHSPC (100; 26.5%) mCRPC (277; 73.5%) treated docetaxel at six public oncology centres were analysed multivariate regression. Primary GCSF prophylaxis was defined as administration within 5 days starting docetaxel. The outcome 21 the first cycle (1st FN). Results given 71 (18.8%) patients. occurred 61 (16.2%) including 37 (9.8%) during cycle. Among who developed 1st (n = 37) or not 340), 2 69 received (5.4 vs. 20.3%, P .03). associated an overall reduced risk (odds ratio [OR] 0.22; 95% confidence interval [CI]: 0.05-0.96, .04), similar trends observed (OR 0.36, .35) 0.16, .08) subgroups. Poor Eastern Cooperative Oncology Group performance status (>1) increased 3.90; CI: 1.66-9.13, .002). Conclusions To alleviate FN, is suggested patients, those poor status.